evidence table

Resveratrol Inflammation Randomized Trial Evidence Table

Structured evidence table for Resveratrol Inflammation Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.

topicclaimevidence levelcitationsource
Resveratrol Inflammation Randomized TrialThe main aim of this systematic review is to comprehensively evaluate and synthesize the current scientific evidence on the role of anthocyanins, curcumin, and resveratrol in the prevention and management of metabolic disorders, with a focus on obesity, type 2 diabetes, and dyslipidemia.1Gazda P (2026)The Role of Anthocyanins, Curcumin, and Resveratrol in the Prevention and Management of Metabolic Disorders: A Systematic Review.
Resveratrol Inflammation Randomized TrialThe analyzed studies demonstrated that anthocyanin supplementation (up to 320 mg/day) was associated with reductions in inflammatory markers such as IL-6 and TNF-α, improvements in HDL cholesterol, and modest reductions in HbA1c (~0.3-0.5%).1Gazda P (2026)The Role of Anthocyanins, Curcumin, and Resveratrol in the Prevention and Management of Metabolic Disorders: A Systematic Review.
Resveratrol Inflammation Randomized TrialCurcumin supplementation was associated with decreases in body weight (up to 0.82 kg), BMI (up to 0.30 kg/m 2 ), triglycerides, total cholesterol, and fasting glucose levels.1Gazda P (2026)The Role of Anthocyanins, Curcumin, and Resveratrol in the Prevention and Management of Metabolic Disorders: A Systematic Review.
Resveratrol Inflammation Randomized TrialMetabolic disorders such as obesity, type 2 diabetes, and lipid disorders are major health challenges worldwide.1Gazda P (2026)The Role of Anthocyanins, Curcumin, and Resveratrol in the Prevention and Management of Metabolic Disorders: A Systematic Review.
Resveratrol Inflammation Randomized TrialAs a result, no phenotype-defined interventional evidence specific to sarcopenic obesity was identified.1Russo C (2026)Vitamin D and resveratrol in sarcopenic obesity: a systematic review highlighting the gap in phenotype-defined randomized controlled trials.
Resveratrol Inflammation Randomized TrialConclusion Despite compelling mechanistic convergence, randomized interventional evidence in strictly defined sarcopenic obesity populations is currently lacking.1Russo C (2026)Vitamin D and resveratrol in sarcopenic obesity: a systematic review highlighting the gap in phenotype-defined randomized controlled trials.
Resveratrol Inflammation Randomized TrialBackground Sarcopenic obesity (SO) is an inflammatory-metabolic condition characterized by the coexistence of excess adiposity and impaired skeletal muscle mass and function.1Russo C (2026)Vitamin D and resveratrol in sarcopenic obesity: a systematic review highlighting the gap in phenotype-defined randomized controlled trials.
Resveratrol Inflammation Randomized TrialVitamin D and resveratrol modulate regulatory pathways implicated in SO pathophysiology, including NF-κB signaling, PGC-1α, mitochondrial regulation, and redox balance.1Russo C (2026)Vitamin D and resveratrol in sarcopenic obesity: a systematic review highlighting the gap in phenotype-defined randomized controlled trials.
topicResveratrol Inflammation Randomized Trial
claimThe main aim of this systematic review is to comprehensively evaluate and synthesize the current scientific evidence on the role of anthocyanins, curcumin, and resveratrol in the prevention and management of metabolic disorders, with a focus on obesity, type 2 diabetes, and dyslipidemia.
evidence level1
citationGazda P (2026)
sourceThe Role of Anthocyanins, Curcumin, and Resveratrol in the Prevention and Management of Metabolic Disorders: A Systematic Review.
topicResveratrol Inflammation Randomized Trial
claimThe analyzed studies demonstrated that anthocyanin supplementation (up to 320 mg/day) was associated with reductions in inflammatory markers such as IL-6 and TNF-α, improvements in HDL cholesterol, and modest reductions in HbA1c (~0.3-0.5%).
evidence level1
citationGazda P (2026)
sourceThe Role of Anthocyanins, Curcumin, and Resveratrol in the Prevention and Management of Metabolic Disorders: A Systematic Review.
topicResveratrol Inflammation Randomized Trial
claimCurcumin supplementation was associated with decreases in body weight (up to 0.82 kg), BMI (up to 0.30 kg/m 2 ), triglycerides, total cholesterol, and fasting glucose levels.
evidence level1
citationGazda P (2026)
sourceThe Role of Anthocyanins, Curcumin, and Resveratrol in the Prevention and Management of Metabolic Disorders: A Systematic Review.
topicResveratrol Inflammation Randomized Trial
claimMetabolic disorders such as obesity, type 2 diabetes, and lipid disorders are major health challenges worldwide.
evidence level1
citationGazda P (2026)
sourceThe Role of Anthocyanins, Curcumin, and Resveratrol in the Prevention and Management of Metabolic Disorders: A Systematic Review.
topicResveratrol Inflammation Randomized Trial
claimAs a result, no phenotype-defined interventional evidence specific to sarcopenic obesity was identified.
evidence level1
citationRusso C (2026)
sourceVitamin D and resveratrol in sarcopenic obesity: a systematic review highlighting the gap in phenotype-defined randomized controlled trials.
topicResveratrol Inflammation Randomized Trial
claimConclusion Despite compelling mechanistic convergence, randomized interventional evidence in strictly defined sarcopenic obesity populations is currently lacking.
evidence level1
citationRusso C (2026)
sourceVitamin D and resveratrol in sarcopenic obesity: a systematic review highlighting the gap in phenotype-defined randomized controlled trials.
topicResveratrol Inflammation Randomized Trial
claimBackground Sarcopenic obesity (SO) is an inflammatory-metabolic condition characterized by the coexistence of excess adiposity and impaired skeletal muscle mass and function.
evidence level1
citationRusso C (2026)
sourceVitamin D and resveratrol in sarcopenic obesity: a systematic review highlighting the gap in phenotype-defined randomized controlled trials.
topicResveratrol Inflammation Randomized Trial
claimVitamin D and resveratrol modulate regulatory pathways implicated in SO pathophysiology, including NF-κB signaling, PGC-1α, mitochondrial regulation, and redox balance.
evidence level1
citationRusso C (2026)
sourceVitamin D and resveratrol in sarcopenic obesity: a systematic review highlighting the gap in phenotype-defined randomized controlled trials.

Learn next

Related evidence and supplement guides

GuideResveratrol Inflammation Randomized Trial: What the Evidence SaysResveratrol Inflammation Randomized Trial has 2 source documents in the current Migaku evidence...GuideResveratrol Skin Aging Randomized Trial: What the Evidence SaysResveratrol Skin Aging Randomized Trial has 2 source documents in the current Migaku evidence da...GuideResveratrol Cognitive Performance Randomized Trial: What the Evidence SaysResveratrol Cognitive Performance Randomized Trial has 1 source documents in the current Migaku...GuideResveratrol Skin Health Randomized Trial: What the Evidence SaysResveratrol Skin Health Randomized Trial has 2 source documents in the current Migaku evidence d...CompareNMN vs ResveratrolNMN acts as the primary 'fuel' that raises cellular NAD+ levels. Resveratrol acts as the 'accele...RankingBest Nootropics for Focus & Attention: 2026 Clinical Evidence ReviewWe separate the clinical evidence from the marketing hype, ranking the most effective brain supp...RankingBest Supplements for Anxiety: Evidence-Based Rankings 2026Anxiety supplements with genuine clinical evidence include ashwagandha (strongest for chronic an...RankingBest Collagen for Hair, Skin & Nails: 2026 Evidence-Based RankingsWe analyzed the amino acid concentrations and molecular weights of top collagen brands to identi...

Source documents

  1. The Role of Anthocyanins, Curcumin, and Resveratrol in the Prevention and Management of Metabolic Disorders: A Systematic Review.
  2. Vitamin D and resveratrol in sarcopenic obesity: a systematic review highlighting the gap in phenotype-defined randomized controlled trials.